Article List
List all articles in the database by earliest discovery_date
GET /articles/?format=api&page=2429
{ "count": 24494, "next": "http://api.gregory-ms.com/articles/?format=api&page=2430", "previous": "http://api.gregory-ms.com/articles/?format=api&page=2428", "results": [ { "article_id": 201, "title": "Effectiveness and safety of alemtuzumab in the treatment of active relapsing-remitting multiple sclerosis: a multicenter, observational study", "summary": "<div><p>Neurol Sci. 2021 Mar 3. doi: 10.1007/s10072-021-05145-x. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">OBJECTIVE: So far, a limited number of real-world evidence studies about the effectiveness and safety of alemtuzumab (ALM) have been published, some of them with a relatively small number of included patients. We aimed to study the efficacy and safety of ALM in real-world clinical practice in two MS centers in Slovenia and Croatia.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: This was a retrospective chart review of 71 consecutive patients with relapsing-remitting MS who were treated with ALM from 2015 till 2018. The following data were collected: gender, age at disease onset, disease duration at ALM initiation, previous disease modifying therapy, number of relapses, active MRI lesions, and EDSS in the year prior to ALM initiation and every year of follow-up.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: All patients completed the standard dosing schedule and were followed for a mean time of 3.2±1.1 years after the initiation of treatment. Complete data for the 2 years after treatment (relapses, EDSS, and MRI) were available for 48 patients, of which 14 (29.2%) achieved NEDA. Clinical NEDA was achieved in 38 out of 63 participants (60.3%). In year 1, 24 out of 57 (42.1%) patients achieved NEDA. In year 2, 26 out of 41 (63.4%) patients achieved NEDA. Lower EDSS prior to starting ALM was the only independent predictor of NEDA in a multivariable model. Adverse events occurred in 58 participants (84.1%), with no new safety signals identified.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSION: According to the data from our cohort of early active RRMS patients we conclude ALM efficacy remains high in the real-world clinical practice.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33660157/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">33660157</a> | DOI:<a href=\"https://doi.org/10.1007/s10072-021-05145-x\">10.1007/s10072-021-05145-x</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33660157/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-11T00:00:00Z", "source": "PubMed", "publisher": "Springer Science and Business Media LLC", "container_title": "Neurological Sciences", "authors": [ { "author_id": 214271, "given_name": "Gregor", "family_name": "Brecl Jakob", "ORCID": "http://orcid.org/0000-0003-4998-5974", "country": "SI" }, { "author_id": 240781, "given_name": "Barbara", "family_name": "Barun", "ORCID": null, "country": null }, { "author_id": 203765, "given_name": "Sarah", "family_name": "Gomezelj", "ORCID": "http://orcid.org/0000-0001-8649-5435", "country": null }, { "author_id": 240782, "given_name": "Tereza", "family_name": "Gabelić", "ORCID": null, "country": null }, { "author_id": 240783, "given_name": "Saša", "family_name": "Šega Jazbec", "ORCID": null, "country": null }, { "author_id": 221943, "given_name": "Ivan", "family_name": "Adamec", "ORCID": "http://orcid.org/0000-0003-3873-6526", "country": null }, { "author_id": 240784, "given_name": "Alenka", "family_name": "Horvat Ledinek", "ORCID": null, "country": null }, { "author_id": 324648, "given_name": "Uroš", "family_name": "Rot", "ORCID": "http://orcid.org/0000-0002-2422-8670", "country": null }, { "author_id": 192760, "given_name": "Magdalena", "family_name": "Krbot Skorić", "ORCID": "http://orcid.org/0000-0002-1087-3732", "country": "HR" }, { "author_id": 161545, "given_name": "Mario", "family_name": "Habek", "ORCID": "http://orcid.org/0000-0002-3360-1748", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-04T12:16:45Z", "noun_phrases": [ "Effectiveness", "safety", "alemtuzumab", "the treatment", "active relapsing-remitting multiple sclerosis", "a multicenter, observational study" ], "doi": "10.1007/s10072-021-05145-x", "access": "restricted", "takeaways": " A limited number of real-world evidence studies about effectiveness and safety of alemtuzumab (ALM) have been published, some of them with a relatively small number of included patients .", "categories": [ { "category_id": 2, "category_description": "LEMTRADA, or Alemtuzumab, is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Since treatment with LEMTRADA can increase your risk of getting certain conditions and diseases, LEMTRADA is generally prescribed for people who have tried 2 or more MS medicines that have not worked well enough. LEMTRADA is not recommended for use in patients with clinically isolated syndrome (CIS). It is not known if LEMTRADA is safe and effective for use in children under 17 years of age.\n\nhttps://www.lemtrada.com/", "category_name": "Alemtuzumab", "category_slug": "alemtuzumab", "category_terms": [ "alemtuzumab", "lemtrada" ], "article_count": 116 } ] }, { "article_id": 214, "title": "Case Report: Anti-MOG Antibody Seroconversion Accompanied by Dimethyl Fumarate Treatment", "summary": "<div><p>Front Immunol. 2021 Feb 15;12:625465. doi: 10.3389/fimmu.2021.625465. eCollection 2021.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">Here we report three cases of anti-myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD) mimicking multiple sclerosis in which seropositivity for anti-MOG antibodies occurred during disease-modifying drug dimethyl fumarate (DMF) treatment. These patients developed relapses with anti-MOG antibody seroconversion after switching from fingolimod or steroid pulse therapy to DMF, which was associated with peripheral lymphocyte recovery. MOGAD is considered a humoral immune disease, and DMF reportedly enhances Th2-skewed humoral immune activity. Therefore, we suggest that DMF, but not fingolimod, may exacerbate humoral immune imbalance and enhance autoantibody production, leading to aggravation of MOGAD.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33659007/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">33659007</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7917254/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">PMC7917254</a> | DOI:<a href=\"https://doi.org/10.3389/fimmu.2021.625465\">10.3389/fimmu.2021.625465</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33659007/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-02-15T00:00:00Z", "source": "PubMed", "publisher": "Frontiers Media SA", "container_title": "Frontiers in Immunology", "authors": [ { "author_id": 253862, "given_name": "Keita", "family_name": "Takahashi", "ORCID": null, "country": null }, { "author_id": 253865, "given_name": "Hideyuki", "family_name": "Takeuchi", "ORCID": null, "country": null }, { "author_id": 253860, "given_name": "Ryoko", "family_name": "Fukai", "ORCID": null, "country": null }, { "author_id": 253858, "given_name": "Haruko", "family_name": "Nakamura", "ORCID": null, "country": null }, { "author_id": 301108, "given_name": "Keisuke", "family_name": "Morihara", "ORCID": null, "country": null }, { "author_id": 301109, "given_name": "Yuichi", "family_name": "Higashiyama", "ORCID": null, "country": null }, { "author_id": 241744, "given_name": "Toshiyuki", "family_name": "Takahashi", "ORCID": null, "country": null }, { "author_id": 253846, "given_name": "Hiroshi", "family_name": "Doi", "ORCID": null, "country": null }, { "author_id": 165173, "given_name": "Fumiaki", "family_name": "Tanaka", "ORCID": "http://orcid.org/0000-0002-9961-2693", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-04T12:16:45Z", "noun_phrases": [ "Case Report", "Anti-MOG Antibody Seroconversion", "Dimethyl Fumarate Treatment" ], "doi": "10.3389/fimmu.2021.625465", "access": "open", "takeaways": " Patients developed relapses with anti-MOG antibody seroconversion after switching from fingolimod or steroid pulse therapy to DMF, which was associated with peripheral lymphocyte recovery . DMF reportedly enhances Th2-skewed humoral", "categories": [ { "category_id": 5, "category_description": "Tecfidera is a medicine used to treat multiple sclerosis (MS), a disease in which inflammation damages the protective insulation around nerves (demyelination) as well as the nerves themselves. It is used in adults and children from 13 years of age with a type of MS known as relapsing-remitting MS, where the patient has flare-ups of symptoms (relapses) followed by periods of recovery (remissions).\r\n\r\nTecfidera contains the active substance dimethyl fumarate.\r\n\r\nhttps://www.ema.europa.eu/en/medicines/human/EPAR/tecfidera", "category_name": "Tecfidera", "category_slug": "tecfidera", "category_terms": [ "tecfidera", "dimethyl fumarate" ], "article_count": 162 } ] }, { "article_id": 203, "title": "Ozanimod for Treatment of Relapsing-Remitting Multiple Sclerosis in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "summary": "<div><p>Front Pharmacol. 2020 Nov 20;11:589146. doi: 10.3389/fphar.2020.589146. eCollection 2020.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\"><b>Background:</b> Ozanimod has been approved for use in the treatment of relapsing forms of multiple sclerosis by the United States FDA. As a novel, orally available sphingosine 1-phosphate receptor modulator, ozanimod selectively binds to S1P1 and S1P5 receptor with high affinity, minimizing safety concerns caused by S1P<sub>3</sub> receptor activation. <b>Methods:</b> e systematically searched PUBMED, EMBASE database, and Cochrane Library database to identify randomized controlled trials (RCTs) from inception to June 28, 2020. Trials were considered eligible if they 1) were randomized clinical trials (RCTs); 2) enrolled adult participants diagnosed with Relapsing-remitting MS; 3) compared ozanimod with placebo or any other approved DMDs that evaluated in phase III or phase II clinical trials; 4) enrolled over 100 participants; 5) provided any available information for predefined primary or secondary outcomes. <b>Results:</b> 2917 participants from three high-quality, multi-centered randomized clinical trials were pooled in our analysis. We found that using ozanimod was significantly associated with the reduction of the annualized relapse rate during the treatment period (RR, -0.10 [95% CI, -0.15, -0.06]). Also, the decreased number of gadolinium-enhancing lesions at the end of the trial was relative to the treatment of ozanimod (ozanimod, 0.29; control, 0.65; RR, -0.20 [95% CI, -0.34, -0.06]). Compared with patients in the control group, the number of new or enlarging T2 lesions over the treatment period decreased in patients treated with ozanimod (ozanimod, 1.82; control, 3.55; RR, -1.12 [95% CI, -1.52, -0.71]). As to the safety endpoints, patients in the ozanimod group reported a lower rate of adverse events (ozanimod, 66.03%; control, 77.07%; RR, 0.64 [95% CI, 0.43, 0.95]). Similar incidence of infection-related TEAEs was found across treatment groups (nasopharyngitis: ozanimod, 11.19%; control, 9.83%; RR, 1.10 [95% CI, 0.77-1.57]; urinary-tract infection: ozanimod, 3.81%; control, 2.97%; RR, 1.29 [95% CI, 0.83-2.00]). No case of macular edema was noted as well as second-degree, type 2, or third-degree atrioventricular block. As for the subgroup analysis, compared with 0.5 mg ozanimod, 1 mg ozanimod is related with a significant reduction of the annualized relapse rate during the treatment period (1 mg ozanimod, 0.18; 0.5 mg ozanimod, 0.24; RR, 0.05 [95% CI, 0.01, 0.09])and a decreased number of new or enlarging T2 lesions over the treatment period (1 mg ozanimod,1.58; 0.5 mg ozanimod, 2.05; RR, 0.49 [95% CI, 0.19, 0.79]). No significant difference in causing adverse events between 1 and 0.5 mg was found. <b>Conclusions:</b> Our meta-analysis found that, with favorable safety performance, the use of ozanimod as a treatment of relapsing-remitting multiple sclerosis in adults was associated with a significant reduction of the annualized relapse rate during the treatment period, decreased number of gadolinium-enhancing lesions at the end of the trial, and lowered number of new or enlarging T2 lesions over the treatment period. Ozanimod 1 mg outperformed 0.5 mg dose in efficacy without increasing the risk of adverse events.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33658933/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">33658933</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7919188/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">PMC7919188</a> | DOI:<a href=\"https://doi.org/10.3389/fphar.2020.589146\">10.3389/fphar.2020.589146</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33658933/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2020-11-20T00:00:00Z", "source": "PubMed", "publisher": "Frontiers Media SA", "container_title": "Frontiers in Pharmacology", "authors": [ { "author_id": 308540, "given_name": "Yue", "family_name": "Sun", "ORCID": null, "country": null }, { "author_id": 308541, "given_name": "Yanbo", "family_name": "Yang", "ORCID": null, "country": null }, { "author_id": 272312, "given_name": "Zilan", "family_name": "Wang", "ORCID": null, "country": null }, { "author_id": 308542, "given_name": "Fan", "family_name": "Jiang", "ORCID": null, "country": null }, { "author_id": 272313, "given_name": "Zhouqing", "family_name": "Chen", "ORCID": null, "country": null }, { "author_id": 174967, "given_name": "Zhong", "family_name": "Wang", "ORCID": "http://orcid.org/0000-0002-7342-0845", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-04T12:16:45Z", "noun_phrases": [ "Ozanimod", "Treatment", "Relapsing-Remitting Multiple Sclerosis", "Adults", "A Systematic Review", "Meta-Analysis", "Randomized Controlled Trials" ], "doi": "10.3389/fphar.2020.589146", "access": "open", "takeaways": " Ozanimod has been approved for use in the treatment of relapsing forms of multiple sclerosis by the U.S. FDA . The number of new or enlarging T2 lesions over the treatment period decreased in patients treated with ozanimod . No significant difference in causing adverse events between 1 and 0.5 mg was found .", "categories": [ { "category_id": 25, "category_description": "Ozanimod", "category_name": "Ozanimod", "category_slug": "ozanimod", "category_terms": [ "ozanimod", "zeposia" ], "article_count": 29 } ] }, { "article_id": 207, "title": "Incorporation and Impact of a Clinical Pharmacist in a Hospital-Based Neurology Clinic Treating Patients with Multiple Sclerosis", "summary": "<div><p>Int J MS Care. 2021 Jan-Feb;23(1):16-20. doi: 10.7224/1537-2073.2019-032. Epub 2020 Feb 14.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND: Clinical pharmacists are uniquely positioned to assist with the complexities of medication management for patients with multiple sclerosis (MS). The objective was to describe clinical pharmacy services provided, as well as provider satisfaction with and perceived impact of incorporating a clinical pharmacist in MS patient care.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: The study consisted of a retrospective medical record review and a provider survey conducted in an outpatient neurology clinic at an academic medical center. Between April 2017 and June 2018, electronic medical records of patients with documented interventions by a pharmacist were reviewed to describe clinical pharmacy services provided to patients with MS. A voluntary, anonymous survey was distributed to neurology providers to evaluate provider satisfaction with and perceived impact of clinical pharmacist involvement in MS patient care.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: There were 64 patients identified with 378 documented interventions made by clinical pharmacists. Pharmacist interventions were mostly related to facilitating medication access (n = 208), pretreatment screening (n = 57), patient counseling (n = 51), and providing drug information (n = 43). All nine providers surveyed indicated that facilitating medication access, counseling patients, and managing drug interactions were moderately or very important clinical pharmacy services. Furthermore, all providers surveyed strongly agreed that pharmacist involvement decreased time to therapy initiation and provider time spent on medication management.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSIONS: Clinical pharmacists play an integral role in MS patient care, particularly with facilitating medication access. Prospective studies are needed to further evaluate the contribution of clinical pharmacists in MS patient care.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33658901/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">33658901</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7906034/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">PMC7906034</a> | DOI:<a href=\"https://doi.org/10.7224/1537-2073.2019-032\">10.7224/1537-2073.2019-032</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33658901/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-01T00:00:00Z", "source": "PubMed", "publisher": "Consortium of Multiple Sclerosis Centers", "container_title": "International Journal of MS Care", "authors": [ { "author_id": 240833, "given_name": "Alexandria", "family_name": "May", "ORCID": null, "country": null }, { "author_id": 240834, "given_name": "Olivia", "family_name": "Morgan", "ORCID": null, "country": null }, { "author_id": 240835, "given_name": "Kristi", "family_name": "Quairoli", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-04T12:16:45Z", "noun_phrases": [ "Incorporation", "Impact", "a Clinical Pharmacist", "a Hospital-Based Neurology Clinic Treating Patients", "Multiple Sclerosis" ], "doi": "10.7224/1537-2073.2019-032", "access": "open", "takeaways": " Clinical pharmacists are uniquely positioned to assist with the complexities of medication management for patients with multiple sclerosis . Pharmacist interventions were mostly related to facilitating medication access, pretreatment screening, patient counseling, and providing drug information .", "categories": [] }, { "article_id": 205, "title": "Prevalence of Latent Tuberculosis in the Multiple Sclerosis Clinic and Effect of Multiple Sclerosis Treatment on Tuberculosis Testing", "summary": "<div><p>Int J MS Care. 2021 Jan-Feb;23(1):26-30. doi: 10.7224/1537-2073.2019-015. Epub 2020 Apr 14.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND: Patients with a compromised immune system are at risk for converting from latent tuberculosis infection (LTBI) to active tuberculosis (TB) infection. Multiple sclerosis (MS) therapies may put individuals with LTBI at higher risk of TB.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: Patients at the Beth Israel Deaconess Medical Center MS Clinic were screened for TB as part of routine testing with the QuantiFERON-TB Gold In-Tube (QFT-GIT) assay (Cellestis Ltd) from 2013 to 2017. Patients were tested either before or during immunomodulatory therapy.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: Four of 222 patients (1.8%; 95% CI, 0.1%-3.6%) had positive QFT-GIT results; three patients had risk factors for TB, having emigrated from TB-endemic countries or worked in the health care industry. Twenty-eight of 222 patients (12.6%) had an indeterminate assay result, and 75.0% of these occurred in patients taking dimethyl fumarate. Fingolimod, natalizumab, or anti-CD20 treatments showed 0% to 7.7% indeterminate results.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSIONS: The prevalence of LTBI was 1.8% in the Beth Israel Deaconess Medical Center MS Clinic. Not all LTBI cases were associated with known risk factors for TB. Screening for LTBI before starting immunosuppressive agents for MS could help prevent activation of TB. Dimethyl fumarate use is associated with indeterminate QFT-GIT results, possibly due to functional effects on lymphocytes and levels of cytokines, such as interferon gamma. In contrast, fingolimod use was rarely associated with indeterminate QFT-GIT results despite a high rate of lymphopenia in virtually all patients.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33658903/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">33658903</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7906031/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">PMC7906031</a> | DOI:<a href=\"https://doi.org/10.7224/1537-2073.2019-015\">10.7224/1537-2073.2019-015</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33658903/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-01T00:00:00Z", "source": "PubMed", "publisher": "Consortium of Multiple Sclerosis Centers", "container_title": "International Journal of MS Care", "authors": [ { "author_id": 240850, "given_name": "Andrew J.", "family_name": "Bouley", "ORCID": null, "country": null }, { "author_id": 240851, "given_name": "Ursela", "family_name": "Baber", "ORCID": null, "country": null }, { "author_id": 240852, "given_name": "Emily", "family_name": "Egnor", "ORCID": null, "country": null }, { "author_id": 240853, "given_name": "Soleil", "family_name": "Samaan", "ORCID": null, "country": null }, { "author_id": 240854, "given_name": "Jacob A.", "family_name": "Sloane", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-04T12:16:45Z", "noun_phrases": [ "Prevalence", "Latent Tuberculosis", "the Multiple Sclerosis Clinic", "Effect", "Multiple Sclerosis Treatment", "Tuberculosis Testing" ], "doi": "10.7224/1537-2073.2019-015", "access": "open", "takeaways": " Patients with a compromised immune system are at risk for converting from latent tuberculosis infection (LTBI) to active tuberculosis (TB) infection . Screening for LTBI before starting immunosuppressive agents could help prevent activation of TB .", "categories": [] }, { "article_id": 210, "title": "Identifying Barriers to and Facilitators of Health Service Access Encountered by Individuals with Multiple Sclerosis", "summary": "<div><p>Int J MS Care. 2021 Jan-Feb;23(1):37-44. doi: 10.7224/1537-2073.2020-026. Epub 2021 Feb 23.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND: The symptoms of multiple sclerosis (MS) can be diverse, complex, and progressive, creating a need for frequent and long-standing health care services. The purpose of this scoping review was to identify the barriers people with MS encounter when attempting to access multidisciplinary health services and the reported facilitators for better access to health services.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: The MEDLINE, Embase, and CINAHL databases were searched, without date or geographic restrictions, using the following terms: <i>multiple sclerosis, health services accessibility, health care access, health care delivery,</i> and <i>delivery of health care</i>. After screening based on exclusion criteria, 23 articles were included in the final review.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: Five main themes were identified as barriers and facilitators to accessing health services: 1) information (information available to people with MS, health care provider knowledge of and familiarity with MS), 2) interactions (interactions between health care providers and people with MS, social networks and support of people with MS, collaboration among health care providers), 3) beliefs and skills (personal values and beliefs, perceived time to travel to and attend appointments, and self-assessment of symptoms and needs of people with MS), 4) practical considerations (wait times, physical barriers, affordability of services), and 5) nature of MS (complexity and unpredictability of disease symptoms).</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSIONS: People with MS and their health care providers may benefit from structured and comprehensive MS-specific education to address barriers to accessing health care services. The education can ultimately facilitate the process of addressing unmet health care needs and contribute to a greater quality of life for people with MS.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33658905/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">33658905</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7906029/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">PMC7906029</a> | DOI:<a href=\"https://doi.org/10.7224/1537-2073.2020-026\">10.7224/1537-2073.2020-026</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33658905/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-01T00:00:00Z", "source": "PubMed", "publisher": "Consortium of Multiple Sclerosis Centers", "container_title": "International Journal of MS Care", "authors": [ { "author_id": 240820, "given_name": "Chantel D.", "family_name": "Mayo", "ORCID": null, "country": null }, { "author_id": 240821, "given_name": "Negar", "family_name": "Farzam-kia", "ORCID": null, "country": null }, { "author_id": 240823, "given_name": "Setareh", "family_name": "Ghahari", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-04T12:16:45Z", "noun_phrases": [ "Barriers", "Facilitators", "Health Service Access", "Individuals", "Multiple Sclerosis" ], "doi": "10.7224/1537-2073.2020-026", "access": "open", "takeaways": " The symptoms of multiple sclerosis (MS) can be diverse, complex, and progressive, creating a need for frequent and long-standing health care services . Five main themes were identified as barriers and facilitators to accessing health services .", "categories": [] }, { "article_id": 204, "title": "Minimally Invasive Oral Surgery Induction of the FRICT-ION Chronic Neuropathic Pain Model", "summary": "<div><p>Bio Protoc. 2020 Apr 20;10(8):e3591. doi: 10.21769/BioProtoc.3591. eCollection 2020 Apr 20.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">An easily induced preclinical trigeminal neuropathic nerve injury model is described here for the study of chronic pain, the model acronym <b>FRICT-ION (F</b>oramen <b>R</b>otundum <b>I</b>nflammatory <b>C</b>onstriction <b>T</b>rigeminal <b>I</b>nfra<b>O</b>rbital <b>N</b>erve). In patients, neuropathic pain is thought to be related to vascular alignment or multiple sclerosis along this small trigeminal nerve branch (V2) innervating the maxillary teeth and middle third of the face. With no detectable outward physical signs, the FRICT-ION model is ideal for blinded studies. The acronym FRICT-ION applied relates to the persistence of the trigeminal neuropathic pain model likely due to sliding irritation with normal chewing in the mice. A step-by-step method to induce the mild chronic rodent neuropathic pain model is described here. The surgery is performed orally through a tiny surgical slit inside the cheek crease to align a chromic gut suture irritant along the nerve as it passes into the skull. The model allows testing of non-evoked subjective measures and evoked quantitative mechanical hypersensitivity (allodynia) testing with von Frey filaments through at least 10-14 weeks (100 days). Anxiety and depression behaviors develop within 3-6 weeks relevant to the affective component of chronic pain. While many pain drugs have failed based on testing performed in the acute animal models available, the more stable and easily replicated trigeminal inflammatory compression model is the better suited for understanding both mechanistic and affective components of nerve injury-induced chronic neuropathic pain states as well as the more ideal for preclinical trials of novel non-opioid pain relief therapies.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33659557/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">33659557</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7842532/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">PMC7842532</a> | DOI:<a href=\"https://doi.org/10.21769/BioProtoc.3591\">10.21769/BioProtoc.3591</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33659557/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2020-04-19T23:00:00Z", "source": "PubMed", "publisher": "Bio-Protocol, LLC", "container_title": "BIO-PROTOCOL", "authors": [ { "author_id": 240825, "given_name": "Maren", "family_name": "Montera", "ORCID": null, "country": null }, { "author_id": 240826, "given_name": "Karin", "family_name": "Westlund", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-04T12:16:45Z", "noun_phrases": [ "Minimally Invasive Oral Surgery Induction", "the FRICT-ION Chronic Neuropathic Pain Model" ], "doi": "10.21769/BioProtoc.3591", "access": "open", "takeaways": " In patients, neuropathic pain is thought to be related to vascular alignment or multiple sclerosis along this small trigeminal nerve branch (V2) innervating the maxillary teeth and middle third of the face . With no detectable outward physical signs, the FRICT-ION model is ideal for blinded studies .", "categories": [] }, { "article_id": 209, "title": "Modeling the Multiple Sclerosis Specialist Nurse Workforce by Determination of Optimum Caseloads in the United Kingdom", "summary": "<div><p>Int J MS Care. 2021 Jan-Feb;23(1):1-7. doi: 10.7224/1537-2073.2019-058. Epub 2020 Jan 13.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND: It is estimated that there are more than 100,000 people in the United Kingdom who have multiple sclerosis (MS). Patient experience and outcome are improved by access to a specialist nursing service. The aim of this study was to perform demand modeling to understand the need for MS nursing interventions, and thus inform modeling of the future UK MS nursing workforce.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: Existing national data and specific workload and service data were collected from 163 MS specialist nurses who completed a questionnaire on activity and complexity of work both done and left undone.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: Data were received from across all of the United Kingdom. Twenty-nine percent of respondents were specialist nurses in the field for 3 years or less. Unpaid overtime was regularly performed by 83.4% of respondents. The MS specialist nurse was part of all areas of the patient journey. Areas of work left undone were psychological interventions, physical assessments, social interventions/benefits, and recommending or prescribing medications.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSIONS: The current recommended caseload of 358 people with MS per full-time equivalent seems to be too high, with a considerable amount of work left undone, particularly psychosocial care. Factors such as travel time, complexity of caseload, changing drug therapies, and societal issues such as the benefits system contributed to driving demand/workload.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33658899/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">33658899</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7906027/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">PMC7906027</a> | DOI:<a href=\"https://doi.org/10.7224/1537-2073.2019-058\">10.7224/1537-2073.2019-058</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33658899/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-01T00:00:00Z", "source": "PubMed", "publisher": "Consortium of Multiple Sclerosis Centers", "container_title": "International Journal of MS Care", "authors": [ { "author_id": 240848, "given_name": "Alison", "family_name": "Leary", "ORCID": null, "country": null }, { "author_id": 240837, "given_name": "Geoffrey", "family_name": "Punshon", "ORCID": null, "country": null }, { "author_id": 240839, "given_name": "Jo", "family_name": "Sopala", "ORCID": null, "country": null }, { "author_id": 240841, "given_name": "Guy", "family_name": "Hannan", "ORCID": null, "country": null }, { "author_id": 240843, "given_name": "Megan", "family_name": "Roberts", "ORCID": null, "country": null }, { "author_id": 240845, "given_name": "Karen", "family_name": "Vernon", "ORCID": null, "country": null }, { "author_id": 240847, "given_name": "Annabella", "family_name": "Pearce", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-04T12:16:45Z", "noun_phrases": [ "the Multiple Sclerosis Specialist Nurse Workforce", "Determination", "Optimum Caseloads", "the United Kingdom" ], "doi": "10.7224/1537-2073.2019-058", "access": "open", "takeaways": " More than 100,000 people in the UK have multiple sclerosis (MS) Patient experience and outcome are improved by access to a specialist nursing service . Unpaid overtime was regularly performed by 83.4% of respondents .", "categories": [] }, { "article_id": 208, "title": "Comparison of the Psychometric Properties of Three Fatigue Scales in Persian-Speaking Patients with Multiple Sclerosis", "summary": "<div><p>Int J MS Care. 2021 Jan-Feb;23(1):8-15. doi: 10.7224/1537-2073.2019-051. Epub 2020 Feb 14.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND: Fatigue is the most disabling symptom in patients with multiple sclerosis (MS). Although there is no standard tool to evaluate fatigue in clinical settings, the Fatigue Impact Scale (FIS), Fatigue Severity Scale (FSS), and Multidimensional Assessment of Fatigue (MAF) scale are popular instruments for this purpose. The aim of this study was to compare the psychometric properties of the Persian versions of these scales.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: One hundred thirty adult patients with MS and 60 controls participated in this study. They completed the scales on two occasions 3 days apart. Reproducibility and internal consistency were evaluated as intraclass correlation coefficients (ICCs) and Cronbach α. Convergent validity was assessed by evaluating the association of the fatigue scales with age, sex, Expanded Disability Status Scale (EDSS) score, disease duration, and sleep quality. Dimensionality was evaluated using confirmatory factor analysis. Acceptability and known-group validity were investigated. The effect size of each scale was computed.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: The ICC of all instruments was 0.99. Internal consistency was 0.97 for the MAF scale, 0.93 for FSS, and 0.83 for FIS. The instruments showed moderate-to-good correlations with Pittsburgh Sleep Quality Index, EDSS score, and disease duration. Acceptability was acceptable. The FIS had three dimensions, and the FSS and MAF scale were unidimensional. All scales were able to discriminate patients with MS from controls.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSIONS: The Persian version of the MAF scale seems to be the most suitable instrument to evaluate fatigue in patients with MS based on its time efficiency, effect size, and detailed data about various aspects of fatigue.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33658900/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">33658900</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7906033/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">PMC7906033</a> | DOI:<a href=\"https://doi.org/10.7224/1537-2073.2019-051\">10.7224/1537-2073.2019-051</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33658900/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-01T00:00:00Z", "source": "PubMed", "publisher": "Consortium of Multiple Sclerosis Centers", "container_title": "International Journal of MS Care", "authors": [ { "author_id": 240863, "given_name": "Shabnam", "family_name": "Behrangrad", "ORCID": null, "country": null }, { "author_id": 240864, "given_name": "Amin Kordi", "family_name": "Yoosefinejad", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-04T12:16:45Z", "noun_phrases": [ "Comparison", "the Psychometric Properties", "Three Fatigue Scales", "Persian-Speaking Patients", "Multiple Sclerosis" ], "doi": "10.7224/1537-2073.2019-051", "access": "open", "takeaways": " Fatigue is the most disabling symptom in patients with multiple sclerosis . Fatigue Impact Scale, Fatigue Severity Scale, and Multidimensional Assessment of Fatigue (MAF) scales are popular instruments for this purpose .", "categories": [] }, { "article_id": 206, "title": "Social Cognitive Theory and Physical Activity in Older Adults with Multiple Sclerosis", "summary": "<div><p>Int J MS Care. 2021 Jan-Feb;23(1):21-25. doi: 10.7224/1537-2073.2019-071. Epub 2020 Feb 14.</p><p><b>ABSTRACT</b></p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">BACKGROUND: The expanding population of older adults with multiple sclerosis (MS) likely experiences many of the same benefits of physical activity (PA) as younger and middle-aged adults with MS. However, participation in PA is exceedingly low in this segment of the MS population. This study examined variables from social cognitive theory (SCT) as correlates of PA in older adults with MS to inform the subsequent development of behavioral interventions.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">METHODS: Older adults with MS (≥60 years of age, N = 180) completed an online survey including demographic and clinical characteristics, SCT variables (exercise self-efficacy, exercise goal setting, social support, and outcome expectations), and PA (total PA [TPA] and moderate-to-vigorous PA [MVPA]).</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">RESULTS: Bivariate correlation analyses indicated that all SCT variables were significantly associated with TPA and MVPA (all <i>P</i> ≤ .001). Hierarchical linear regression analyses indicated that disability status was a significant correlate of TPA (<i>β</i> = -0.48, <i>R<sup>2</sup></i> = 0.23) and MVPA (<i>β</i> = -0.44, <i>R<sup>2</sup></i> = 0.19) in step 1; disability and self-efficacy were significant correlates of TPA (disability <i>β</i> = -0.20, self-efficacy <i>β</i> = 0.59, <i>R<sup>2</sup></i> = 0.50) and MVPA (disability <i>β</i> = -0.16, self-efficacy <i>β</i> = 0.60, <i>R<sup>2</sup></i> = 0.47) in step 2; and disability, self-efficacy, and exercise goal setting were significant correlates of TPA (disability <i>β</i> = -0.21, self-efficacy <i>β</i> = 0.50, exercise goal setting <i>β</i> = 0.14, <i>R<sup>2</sup></i> = 0.55) and MVPA (disability <i>β</i> = -0.17, self-efficacy <i>β</i> = 0.51, exercise goal setting <i>β</i> = 0.15, <i>R<sup>2</sup></i> = 0.51) in step 3.</p><p xmlns:mml=\"http://www.w3.org/1998/Math/MathML\" xmlns:p1=\"http://pubmed.gov/pub-one\" xmlns:xlink=\"http://www.w3.org/1999/xlink\">CONCLUSIONS: These results suggest that behavioral interventions focusing on self-efficacy and exercise goal setting as targets from SCT may be appropriate for increasing PA in older adults with MS.</p><p>PMID:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33658902/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">33658902</a> | PMC:<a href=\"https://www.ncbi.nlm.nih.gov/pmc/PMC7906028/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20210304071644&v=2.14.2\">PMC7906028</a> | DOI:<a href=\"https://doi.org/10.7224/1537-2073.2019-071\">10.7224/1537-2073.2019-071</a></p></div>", "link": "https://pubmed.ncbi.nlm.nih.gov/33658902/#x3D;Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc&#x", "published_date": "2021-01-01T00:00:00Z", "source": "PubMed", "publisher": "Consortium of Multiple Sclerosis Centers", "container_title": "International Journal of MS Care", "authors": [ { "author_id": 186904, "given_name": "Jessica F.", "family_name": "Baird", "ORCID": "http://orcid.org/0000-0002-0691-049X", "country": null }, { "author_id": 153224, "given_name": "Stephanie L.", "family_name": "Silveira", "ORCID": "http://orcid.org/0000-0002-1973-2119", "country": null }, { "author_id": 157564, "given_name": "Robert W.", "family_name": "Motl", "ORCID": "http://orcid.org/0000-0003-0112-2803", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2021-03-04T12:16:45Z", "noun_phrases": [ "Social Cognitive Theory", "Physical Activity", "Older Adults", "Multiple Sclerosis" ], "doi": "10.7224/1537-2073.2019-071", "access": "open", "takeaways": " The expanding population of older adults with multiple sclerosis likely experiences many of the same benefits of physical activity (PA) as younger and middle-aged adults with MS . Participation in PA is exceedingly low in this segment of the MS population .", "categories": [] } ] }